Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on November 22, 2024. The filing announces the date for the 2025 Annual Meeting of Stockholders and outlines the deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder meeting logistics.
Material Changes
There are no material financial changes reported in this document. The primary event is the scheduling of the 2025 Annual Meeting for January 30, 2025, with a record date of December 9, 2024.
Guidance, Outlook, and Governance Deadlines
- Annual Meeting Date: January 30, 2025.
- Record Date: December 9, 2024 (stockholders of record as of this date are entitled to vote).
- Rule 14a-8 Proposals: Proposals for inclusion in proxy materials must be received by December 10, 2024.
- Director Nominations (Outside Rule 14a-8): The deadline for notice of director nominations or proposals under the Company's Bylaws was September 18, 2024. This deadline has passed.
Key Facts for Investor Verification
- Verify the correct registrant name is MEI Pharma, Inc. (Ticker: MEIP), as the input metadata referenced "Lite Strategy, Inc."
- Confirm the record date of December 9, 2024 to determine voting eligibility for the January 30, 2025 meeting.
- Note that the deadline for submitting director nominations outside of Rule 14a-8 has already expired as of September 18, 2024.
- Check for any subsequent filings regarding the actual proxy statement to be distributed prior to the annual meeting.